Diuretika-Therapie

Abstract

The treatment of generalized edema includes primarily the treatment of the underlying disease as well as the sodium restriction. Often, however, the volume balance alone can not be controlled satisfactorily. Commonly, diuretics are used for the treatment of chronic heart failure, liver cirrhosis, nephrotic syndrome and renal failure. Diuretics are well documented effective and necessary drugs for the treatment of hypervolemia. From a symptomatic point of view, they are indispensable for cardiac decompensation and they have a firm place in the treatment of hypertension. Due to the different effects as well as pharmacological differences, diuretics can be used for differential therapeutics. The therapy can be associated with side effects. Sequential nephron blockade may be useful in diuretic resistance, but evidence in controlled trials is still lacking. This review provides an overview of the mechanisms, diuretic use and diuretic resistance.

Diuretika sind wirksam und notwendig bei der Behandlung einer Hypervolämie. Aus symptomatischer Sicht sind sie unverzichtbar bei kardialer Dekompensation, und auch in der Therapie der Hypertonie haben sie einen festen Stellenwert. Aufgrund ihrer pharmakologischen Unterschiede sind Diuretika breit einsetzbar, jedoch sind auch die Nebenwirkungen zu beachten. Dieser Beitrag informiert über Wirkmechanismen, klinischen Einsatz und Diuretika-Resistenz.

Schlüsselwörter

Schleifendiuretika - Thiazide - Ödeme - Natriumrestriktion - Diuretika-Resistenz

Key words

loop diuretics - thiazides - edema - sodium restriction - diuretic resistance

• Literatur

• 1 Somasekharan S, Tanis J, Forbush B. Loop diuretics and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl-cotransporter (NKCC1). J Biol Chem 2012; 287: 17908-17917
• 2 Oppermann M, Hansen PB, Castrop H. et al. Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am J Physiol Renal Physiol 2007; 293 (01) F279-F287
• 3 Palmer LG, Schnerrmann J. Integrated control of Na transport along the nephron. Clin J Am Soc Nephrol 2015; 10: 676-687
• 4 Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med 2016; 375: 2096-2098
• 5 Udelson JE, Orlandi C, Ouyang J. et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545
• 6 Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36 (04) 682-689
• 7 Fliser D, Schröter M, Neubeck M. et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46 (02) 482-488
• 8 ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288 (23) 2981-2997
• 9 Bagshaw SM, Delaney A, Haase M. et al. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc 2007; 9: 60-68
• 10 Chawla LS, Davison DL, Brasha-Mitchell E. et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013; 17: R207
• 11 Uchida T, Yamanaga K, Nishikawa M. et al. Anti-aldosteronergic effect of torasemid. Eur J Pharmacol 1991; 205 (02) 145-150
• 12 Leonard CE, Razzaghi H, Freeman CP. et al. Empiric Potassium Supplementation and Increased Survival in Users of Loop Diuretics. PLoS ONE 2014; 9 (07) e102279
• 13 Dai LJ, Friedman PA, Quamme GA. Phosphate depletion diminishes Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997; 51 (06) 1710-1718
• 14 Elliot WJ, Meyer PN. Incident diabetes in clinical trials of antihypertensive drugs: a network meta analysis. Lancet 2007; 369: 201-207
• 15 Brown MJ, Wiiliams B, Morant SV. et al. Effect of amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomized phase 4 trial. Lancet 2016; 4 (02) 136-147
• 16 Pedersen SA, Gaist D, Schmidt SAJ. et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (04) 673-681
• 17 Verdel BM, van Puijenbroek EP, Souverein PC. et al. Drug-related nephrotoxic and ototoxic reactions: a link through a predictive mechanistic commonality. Drug Safety 2008; 31 (10) 877-884
• 18 Salvador DR, Rey NR, Ramos GC. et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004; (1): CD003178